Genomic Cancer Panel & Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing), By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others), By Application (Clinical, Research), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others), By Region & Competition, 2021-2031F
The Global Genomic Cancer Panel & Profiling Market is projected to expand from a valuation of USD 11.09 Billion in 2025 to USD 19.16 Billion by 2031, registering a CAGR of 9.54%. These diagnostic technologies focus on sequencing specific genes or genomic regions to pinpoint mutations and alterations that fuel tumor development. The market?s upward trajectory is largely driven by the growing global incidence of cancer, which demands personalized therapeutic strategies, alongside the decreasing costs associated with next-generation sequencing workflows. Together, these factors encourage the incorporation of extensive molecular diagnostics into clinical settings to optimize targeted treatment planning.
This demand is intensified by the increasing disease burden; the American Cancer Society projects that new cancer cases in the United States will exceed 2 million for the first time in 2024. Despite this evident need, the market contends with significant hurdles related to complex reimbursement structures. Inconsistent insurance coverage for comprehensive molecular profiling continues to be a major obstacle, potentially limiting widespread adoption and restricting patient access to these critical testing capabilities.
Market Driver
The rapid growth of non-invasive liquid biopsy profiling serves as a major market accelerator by addressing the constraints of conventional tissue sampling. These blood-based assays facilitate the detection of circulating tumor DNA, allowing for real-time tracking of disease progression and resistance mechanisms without the dangers linked to surgical biopsies. The shift toward less invasive diagnostics is underscored by increasing clinical testing volumes; for instance, Guardant Health reported in its November 2024 Third Quarter Financial Results that clinical test volume rose 21% year-over-year to 53,100 tests, signaling rapid clinical adoption of these tools.
Concurrently, the rise in biomarker-driven drug development requires the use of comprehensive genomic panels to identify candidates for targeted therapies. Pharmaceutical companies are heavily investing in precision oncology portfolios, fueling the need for companion diagnostics. Highlighting the commercial value of biomarker-targeted treatments, Pfizer reported in its October 2024 Third Quarter Results that oncology revenue was bolstered by an $854 million contribution from the acquired Seagen portfolio. This investment aligns with long-term forecasts of disease burden, as the World Health Organization?s International Agency for Research on Cancer predicted in 2024 that global cancer cases will exceed 35 million by 2050, emphasizing the urgency for scalable diagnostic solutions.
Market Challenge
Complicated reimbursement landscapes and inconsistent insurance coverage represent substantial obstacles to the expansion of the Global Genomic Cancer Panel & Profiling Market. Clinical laboratories and hospital systems are often reluctant to incorporate comprehensive genomic profiling into routine care when payment structures are unclear or unpredictable. This financial instability forces healthcare providers to depend on narrower, less costly diagnostic tests to prevent claim denials, which hinders the uptake of broader next-generation sequencing panels. Consequently, market expansion is stifled because financial administrators at medical facilities often view the economic risks of these advanced diagnostics as outweighing their clinical benefits.
Furthermore, the lack of uniformity in payer policies limits the total volume of testing and restricts revenue opportunities for diagnostic firms. Without standardized mandates, patients frequently encounter prohibitive out-of-pocket expenses, resulting in high rates of test abandonment. According to the American Cancer Society Cancer Action Network in 2024, only 16 states had enacted legislation guaranteeing coverage for comprehensive biomarker testing, leaving most of the United States population facing fragmented and restrictive insurance decisions. This regulatory patchwork creates a market where access depends more on geography and insurance plan type than on clinical necessity, effectively capping market penetration and growth.
Market Trends
The integration of Artificial Intelligence in Data Interpretation is transforming the market by addressing the challenge of analyzing vast genomic datasets. As sequencing outputs increase in complexity, AI algorithms have become crucial for deriving clinical insights and detecting rare variant patterns that might be overlooked during manual analysis. This technological convergence is driving commercial adoption, with diagnostic companies utilizing AI to refine precision medicine capabilities and boost operational efficiency. For example, Tempus AI reported in its January 2025 Preliminary Fourth Quarter and Full Year 2024 Results that full-year revenue reached approximately $693 million, marking a 30% year-over-year increase attributed largely to the strong adoption of its AI-powered precision medicine and genomic profiling solutions.
At the same time, the market is undergoing a distinct transition toward Comprehensive Genomic Profiling (CGP), moving away from limited hotspot panels in favor of broad-spectrum sequencing. This evolution is driven by emerging clinical data indicating that larger panels identify a significantly higher number of actionable alterations, thereby enhancing patient access to matched therapies relative to narrower diagnostic methods. This distinct clinical advantage is prompting healthcare systems to standardize broader testing protocols to reduce missed treatment opportunities. As noted by Illumina in a November 2024 press release regarding a new joint study, real-world evidence showed that 67% of tumors from CGP-tested patients contained actionable mutations, compared to just 33% in patients assessed with smaller 50-gene panels.
Key Market Players
%li%Agilent Technologies, Inc.
%li%ARUP Laboratories Inc
%li%Burning Rock Biotech Limited
%li%U.S. Caris MPI, Inc.
%li%Danaher Corporation
%li%Exact Sciences Corporation
%li%F. Hoffmann-La Roche Ltd
%li%Fulgent Genetics Inc.
%li%Illumina, Inc.
%li%Thermo Fisher Scientific Inc.
Report Scope
In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
%li%Genomic Cancer Panel & Profiling Market, By Tissue Testing
%li%%li%Solid Tissue Testing
%li%%li%Liquid Tissue Testing
%li%Genomic Cancer Panel & Profiling Market, By Cancer Panel Type
%li%%li%Single-Gene Panel
%li%%li%Multi-Gene Panel
%li%Genomic Cancer Panel & Profiling Market, By Cancer Type
%li%%li%Lung Cancer
%li%%li%Breast Cancer
%li%%li%Colon Cancer
%li%%li%Prostate Cancer
%li%%li%Others
%li%Genomic Cancer Panel & Profiling Market, By Application
%li%%li%Clinical
%li%%li%Research
%li%Genomic Cancer Panel & Profiling Market, By Technology
%li%%li%Next-Generation Sequencing (NGS)
%li%%li%Polymerase Chain Reaction (PCR)
%li%%li%Fluorescence In-Situ Hybridization (FISH)
%li%%li%Immunohistochemistry (IHC)
%li%%li%Others
%li%Genomic Cancer Panel & Profiling Market, By End-User
%li%%li%Hospitals
%li%%li%Clinical and Diagnostic Laboratories
%li%%li%Others
%li%Genomic Cancer Panel & Profiling Market, By Region
%li%%li%North America
%li%%li%%li%United States
%li%%li%%li%Canada
%li%%li%%li%Mexico
%li%%li%Europe
%li%%li%%li%France
%li%%li%%li%United Kingdom
%li%%li%%li%Italy
%li%%li%%li%Germany
%li%%li%%li%Spain
%li%%li%Asia Pacific
%li%%li%%li%China
%li%%li%%li%India
%li%%li%%li%Japan
%li%%li%%li%Australia
%li%%li%%li%South Korea
%li%%li%South America
%li%%li%%li%Brazil
%li%%li%%li%Argentina
%li%%li%%li%Colombia
%li%%li%Middle East & Africa
%li%%li%%li%South Africa
%li%%li%%li%Saudi Arabia
%li%%li%%li%UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Genomic Cancer Panel & Profiling Market.
Available Customizations:
Global Genomic Cancer Panel & Profiling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
%li%Detailed analysis and profiling of additional market players (up to five).
This demand is intensified by the increasing disease burden; the American Cancer Society projects that new cancer cases in the United States will exceed 2 million for the first time in 2024. Despite this evident need, the market contends with significant hurdles related to complex reimbursement structures. Inconsistent insurance coverage for comprehensive molecular profiling continues to be a major obstacle, potentially limiting widespread adoption and restricting patient access to these critical testing capabilities.
Market Driver
The rapid growth of non-invasive liquid biopsy profiling serves as a major market accelerator by addressing the constraints of conventional tissue sampling. These blood-based assays facilitate the detection of circulating tumor DNA, allowing for real-time tracking of disease progression and resistance mechanisms without the dangers linked to surgical biopsies. The shift toward less invasive diagnostics is underscored by increasing clinical testing volumes; for instance, Guardant Health reported in its November 2024 Third Quarter Financial Results that clinical test volume rose 21% year-over-year to 53,100 tests, signaling rapid clinical adoption of these tools.
Concurrently, the rise in biomarker-driven drug development requires the use of comprehensive genomic panels to identify candidates for targeted therapies. Pharmaceutical companies are heavily investing in precision oncology portfolios, fueling the need for companion diagnostics. Highlighting the commercial value of biomarker-targeted treatments, Pfizer reported in its October 2024 Third Quarter Results that oncology revenue was bolstered by an $854 million contribution from the acquired Seagen portfolio. This investment aligns with long-term forecasts of disease burden, as the World Health Organization?s International Agency for Research on Cancer predicted in 2024 that global cancer cases will exceed 35 million by 2050, emphasizing the urgency for scalable diagnostic solutions.
Market Challenge
Complicated reimbursement landscapes and inconsistent insurance coverage represent substantial obstacles to the expansion of the Global Genomic Cancer Panel & Profiling Market. Clinical laboratories and hospital systems are often reluctant to incorporate comprehensive genomic profiling into routine care when payment structures are unclear or unpredictable. This financial instability forces healthcare providers to depend on narrower, less costly diagnostic tests to prevent claim denials, which hinders the uptake of broader next-generation sequencing panels. Consequently, market expansion is stifled because financial administrators at medical facilities often view the economic risks of these advanced diagnostics as outweighing their clinical benefits.
Furthermore, the lack of uniformity in payer policies limits the total volume of testing and restricts revenue opportunities for diagnostic firms. Without standardized mandates, patients frequently encounter prohibitive out-of-pocket expenses, resulting in high rates of test abandonment. According to the American Cancer Society Cancer Action Network in 2024, only 16 states had enacted legislation guaranteeing coverage for comprehensive biomarker testing, leaving most of the United States population facing fragmented and restrictive insurance decisions. This regulatory patchwork creates a market where access depends more on geography and insurance plan type than on clinical necessity, effectively capping market penetration and growth.
Market Trends
The integration of Artificial Intelligence in Data Interpretation is transforming the market by addressing the challenge of analyzing vast genomic datasets. As sequencing outputs increase in complexity, AI algorithms have become crucial for deriving clinical insights and detecting rare variant patterns that might be overlooked during manual analysis. This technological convergence is driving commercial adoption, with diagnostic companies utilizing AI to refine precision medicine capabilities and boost operational efficiency. For example, Tempus AI reported in its January 2025 Preliminary Fourth Quarter and Full Year 2024 Results that full-year revenue reached approximately $693 million, marking a 30% year-over-year increase attributed largely to the strong adoption of its AI-powered precision medicine and genomic profiling solutions.
At the same time, the market is undergoing a distinct transition toward Comprehensive Genomic Profiling (CGP), moving away from limited hotspot panels in favor of broad-spectrum sequencing. This evolution is driven by emerging clinical data indicating that larger panels identify a significantly higher number of actionable alterations, thereby enhancing patient access to matched therapies relative to narrower diagnostic methods. This distinct clinical advantage is prompting healthcare systems to standardize broader testing protocols to reduce missed treatment opportunities. As noted by Illumina in a November 2024 press release regarding a new joint study, real-world evidence showed that 67% of tumors from CGP-tested patients contained actionable mutations, compared to just 33% in patients assessed with smaller 50-gene panels.
Key Market Players
%li%Agilent Technologies, Inc.
%li%ARUP Laboratories Inc
%li%Burning Rock Biotech Limited
%li%U.S. Caris MPI, Inc.
%li%Danaher Corporation
%li%Exact Sciences Corporation
%li%F. Hoffmann-La Roche Ltd
%li%Fulgent Genetics Inc.
%li%Illumina, Inc.
%li%Thermo Fisher Scientific Inc.
Report Scope
In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
%li%Genomic Cancer Panel & Profiling Market, By Tissue Testing
%li%%li%Solid Tissue Testing
%li%%li%Liquid Tissue Testing
%li%Genomic Cancer Panel & Profiling Market, By Cancer Panel Type
%li%%li%Single-Gene Panel
%li%%li%Multi-Gene Panel
%li%Genomic Cancer Panel & Profiling Market, By Cancer Type
%li%%li%Lung Cancer
%li%%li%Breast Cancer
%li%%li%Colon Cancer
%li%%li%Prostate Cancer
%li%%li%Others
%li%Genomic Cancer Panel & Profiling Market, By Application
%li%%li%Clinical
%li%%li%Research
%li%Genomic Cancer Panel & Profiling Market, By Technology
%li%%li%Next-Generation Sequencing (NGS)
%li%%li%Polymerase Chain Reaction (PCR)
%li%%li%Fluorescence In-Situ Hybridization (FISH)
%li%%li%Immunohistochemistry (IHC)
%li%%li%Others
%li%Genomic Cancer Panel & Profiling Market, By End-User
%li%%li%Hospitals
%li%%li%Clinical and Diagnostic Laboratories
%li%%li%Others
%li%Genomic Cancer Panel & Profiling Market, By Region
%li%%li%North America
%li%%li%%li%United States
%li%%li%%li%Canada
%li%%li%%li%Mexico
%li%%li%Europe
%li%%li%%li%France
%li%%li%%li%United Kingdom
%li%%li%%li%Italy
%li%%li%%li%Germany
%li%%li%%li%Spain
%li%%li%Asia Pacific
%li%%li%%li%China
%li%%li%%li%India
%li%%li%%li%Japan
%li%%li%%li%Australia
%li%%li%%li%South Korea
%li%%li%South America
%li%%li%%li%Brazil
%li%%li%%li%Argentina
%li%%li%%li%Colombia
%li%%li%Middle East & Africa
%li%%li%%li%South Africa
%li%%li%%li%Saudi Arabia
%li%%li%%li%UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Genomic Cancer Panel & Profiling Market.
Available Customizations:
Global Genomic Cancer Panel & Profiling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
%li%Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
5.2.4. By Application (Clinical, Research)
5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
5.2.7. By Region
5.2.8. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Tissue Testing
6.2.2. By Cancer Panel Type
6.2.3. By Cancer Type
6.2.4. By Application
6.2.5. By Technology
6.2.6. By End-User
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Tissue Testing
6.3.1.2.2. By Cancer Panel Type
6.3.1.2.3. By Cancer Type
6.3.1.2.4. By Application
6.3.1.2.5. By Technology
6.3.1.2.6. By End-User
6.3.2. Canada Genomic Cancer Panel & Profiling Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Tissue Testing
6.3.2.2.2. By Cancer Panel Type
6.3.2.2.3. By Cancer Type
6.3.2.2.4. By Application
6.3.2.2.5. By Technology
6.3.2.2.6. By End-User
6.3.3. Mexico Genomic Cancer Panel & Profiling Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Tissue Testing
6.3.3.2.2. By Cancer Panel Type
6.3.3.2.3. By Cancer Type
6.3.3.2.4. By Application
6.3.3.2.5. By Technology
6.3.3.2.6. By End-User
7. EUROPE GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tissue Testing
7.2.2. By Cancer Panel Type
7.2.3. By Cancer Type
7.2.4. By Application
7.2.5. By Technology
7.2.6. By End-User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genomic Cancer Panel & Profiling Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tissue Testing
7.3.1.2.2. By Cancer Panel Type
7.3.1.2.3. By Cancer Type
7.3.1.2.4. By Application
7.3.1.2.5. By Technology
7.3.1.2.6. By End-User
7.3.2. France Genomic Cancer Panel & Profiling Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tissue Testing
7.3.2.2.2. By Cancer Panel Type
7.3.2.2.3. By Cancer Type
7.3.2.2.4. By Application
7.3.2.2.5. By Technology
7.3.2.2.6. By End-User
7.3.3. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tissue Testing
7.3.3.2.2. By Cancer Panel Type
7.3.3.2.3. By Cancer Type
7.3.3.2.4. By Application
7.3.3.2.5. By Technology
7.3.3.2.6. By End-User
7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Tissue Testing
7.3.4.2.2. By Cancer Panel Type
7.3.4.2.3. By Cancer Type
7.3.4.2.4. By Application
7.3.4.2.5. By Technology
7.3.4.2.6. By End-User
7.3.5. Spain Genomic Cancer Panel & Profiling Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Tissue Testing
7.3.5.2.2. By Cancer Panel Type
7.3.5.2.3. By Cancer Type
7.3.5.2.4. By Application
7.3.5.2.5. By Technology
7.3.5.2.6. By End-User
8. ASIA PACIFIC GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tissue Testing
8.2.2. By Cancer Panel Type
8.2.3. By Cancer Type
8.2.4. By Application
8.2.5. By Technology
8.2.6. By End-User
8.2.7. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genomic Cancer Panel & Profiling Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tissue Testing
8.3.1.2.2. By Cancer Panel Type
8.3.1.2.3. By Cancer Type
8.3.1.2.4. By Application
8.3.1.2.5. By Technology
8.3.1.2.6. By End-User
8.3.2. India Genomic Cancer Panel & Profiling Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tissue Testing
8.3.2.2.2. By Cancer Panel Type
8.3.2.2.3. By Cancer Type
8.3.2.2.4. By Application
8.3.2.2.5. By Technology
8.3.2.2.6. By End-User
8.3.3. Japan Genomic Cancer Panel & Profiling Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tissue Testing
8.3.3.2.2. By Cancer Panel Type
8.3.3.2.3. By Cancer Type
8.3.3.2.4. By Application
8.3.3.2.5. By Technology
8.3.3.2.6. By End-User
8.3.4. South Korea Genomic Cancer Panel & Profiling Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Tissue Testing
8.3.4.2.2. By Cancer Panel Type
8.3.4.2.3. By Cancer Type
8.3.4.2.4. By Application
8.3.4.2.5. By Technology
8.3.4.2.6. By End-User
8.3.5. Australia Genomic Cancer Panel & Profiling Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Tissue Testing
8.3.5.2.2. By Cancer Panel Type
8.3.5.2.3. By Cancer Type
8.3.5.2.4. By Application
8.3.5.2.5. By Technology
8.3.5.2.6. By End-User
9. MIDDLE EAST & AFRICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tissue Testing
9.2.2. By Cancer Panel Type
9.2.3. By Cancer Type
9.2.4. By Application
9.2.5. By Technology
9.2.6. By End-User
9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tissue Testing
9.3.1.2.2. By Cancer Panel Type
9.3.1.2.3. By Cancer Type
9.3.1.2.4. By Application
9.3.1.2.5. By Technology
9.3.1.2.6. By End-User
9.3.2. UAE Genomic Cancer Panel & Profiling Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tissue Testing
9.3.2.2.2. By Cancer Panel Type
9.3.2.2.3. By Cancer Type
9.3.2.2.4. By Application
9.3.2.2.5. By Technology
9.3.2.2.6. By End-User
9.3.3. South Africa Genomic Cancer Panel & Profiling Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tissue Testing
9.3.3.2.2. By Cancer Panel Type
9.3.3.2.3. By Cancer Type
9.3.3.2.4. By Application
9.3.3.2.5. By Technology
9.3.3.2.6. By End-User
10. SOUTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tissue Testing
10.2.2. By Cancer Panel Type
10.2.3. By Cancer Type
10.2.4. By Application
10.2.5. By Technology
10.2.6. By End-User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tissue Testing
10.3.1.2.2. By Cancer Panel Type
10.3.1.2.3. By Cancer Type
10.3.1.2.4. By Application
10.3.1.2.5. By Technology
10.3.1.2.6. By End-User
10.3.2. Colombia Genomic Cancer Panel & Profiling Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tissue Testing
10.3.2.2.2. By Cancer Panel Type
10.3.2.2.3. By Cancer Type
10.3.2.2.4. By Application
10.3.2.2.5. By Technology
10.3.2.2.6. By End-User
10.3.3. Argentina Genomic Cancer Panel & Profiling Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tissue Testing
10.3.3.2.2. By Cancer Panel Type
10.3.3.2.3. By Cancer Type
10.3.3.2.4. By Application
10.3.3.2.5. By Technology
10.3.3.2.6. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Agilent Technologies, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. ARUP Laboratories Inc
15.3. Burning Rock Biotech Limited
15.4. U.S. Caris MPI, Inc.
15.5. Danaher Corporation
15.6. Exact Sciences Corporation
15.7. F. Hoffmann-La Roche Ltd
15.8. Fulgent Genetics Inc.
15.9. Illumina, Inc.
15.10. Thermo Fisher Scientific Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
5.2.4. By Application (Clinical, Research)
5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
5.2.7. By Region
5.2.8. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Tissue Testing
6.2.2. By Cancer Panel Type
6.2.3. By Cancer Type
6.2.4. By Application
6.2.5. By Technology
6.2.6. By End-User
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Tissue Testing
6.3.1.2.2. By Cancer Panel Type
6.3.1.2.3. By Cancer Type
6.3.1.2.4. By Application
6.3.1.2.5. By Technology
6.3.1.2.6. By End-User
6.3.2. Canada Genomic Cancer Panel & Profiling Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Tissue Testing
6.3.2.2.2. By Cancer Panel Type
6.3.2.2.3. By Cancer Type
6.3.2.2.4. By Application
6.3.2.2.5. By Technology
6.3.2.2.6. By End-User
6.3.3. Mexico Genomic Cancer Panel & Profiling Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Tissue Testing
6.3.3.2.2. By Cancer Panel Type
6.3.3.2.3. By Cancer Type
6.3.3.2.4. By Application
6.3.3.2.5. By Technology
6.3.3.2.6. By End-User
7. EUROPE GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tissue Testing
7.2.2. By Cancer Panel Type
7.2.3. By Cancer Type
7.2.4. By Application
7.2.5. By Technology
7.2.6. By End-User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genomic Cancer Panel & Profiling Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tissue Testing
7.3.1.2.2. By Cancer Panel Type
7.3.1.2.3. By Cancer Type
7.3.1.2.4. By Application
7.3.1.2.5. By Technology
7.3.1.2.6. By End-User
7.3.2. France Genomic Cancer Panel & Profiling Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tissue Testing
7.3.2.2.2. By Cancer Panel Type
7.3.2.2.3. By Cancer Type
7.3.2.2.4. By Application
7.3.2.2.5. By Technology
7.3.2.2.6. By End-User
7.3.3. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tissue Testing
7.3.3.2.2. By Cancer Panel Type
7.3.3.2.3. By Cancer Type
7.3.3.2.4. By Application
7.3.3.2.5. By Technology
7.3.3.2.6. By End-User
7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Tissue Testing
7.3.4.2.2. By Cancer Panel Type
7.3.4.2.3. By Cancer Type
7.3.4.2.4. By Application
7.3.4.2.5. By Technology
7.3.4.2.6. By End-User
7.3.5. Spain Genomic Cancer Panel & Profiling Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Tissue Testing
7.3.5.2.2. By Cancer Panel Type
7.3.5.2.3. By Cancer Type
7.3.5.2.4. By Application
7.3.5.2.5. By Technology
7.3.5.2.6. By End-User
8. ASIA PACIFIC GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tissue Testing
8.2.2. By Cancer Panel Type
8.2.3. By Cancer Type
8.2.4. By Application
8.2.5. By Technology
8.2.6. By End-User
8.2.7. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genomic Cancer Panel & Profiling Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tissue Testing
8.3.1.2.2. By Cancer Panel Type
8.3.1.2.3. By Cancer Type
8.3.1.2.4. By Application
8.3.1.2.5. By Technology
8.3.1.2.6. By End-User
8.3.2. India Genomic Cancer Panel & Profiling Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tissue Testing
8.3.2.2.2. By Cancer Panel Type
8.3.2.2.3. By Cancer Type
8.3.2.2.4. By Application
8.3.2.2.5. By Technology
8.3.2.2.6. By End-User
8.3.3. Japan Genomic Cancer Panel & Profiling Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tissue Testing
8.3.3.2.2. By Cancer Panel Type
8.3.3.2.3. By Cancer Type
8.3.3.2.4. By Application
8.3.3.2.5. By Technology
8.3.3.2.6. By End-User
8.3.4. South Korea Genomic Cancer Panel & Profiling Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Tissue Testing
8.3.4.2.2. By Cancer Panel Type
8.3.4.2.3. By Cancer Type
8.3.4.2.4. By Application
8.3.4.2.5. By Technology
8.3.4.2.6. By End-User
8.3.5. Australia Genomic Cancer Panel & Profiling Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Tissue Testing
8.3.5.2.2. By Cancer Panel Type
8.3.5.2.3. By Cancer Type
8.3.5.2.4. By Application
8.3.5.2.5. By Technology
8.3.5.2.6. By End-User
9. MIDDLE EAST & AFRICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tissue Testing
9.2.2. By Cancer Panel Type
9.2.3. By Cancer Type
9.2.4. By Application
9.2.5. By Technology
9.2.6. By End-User
9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tissue Testing
9.3.1.2.2. By Cancer Panel Type
9.3.1.2.3. By Cancer Type
9.3.1.2.4. By Application
9.3.1.2.5. By Technology
9.3.1.2.6. By End-User
9.3.2. UAE Genomic Cancer Panel & Profiling Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tissue Testing
9.3.2.2.2. By Cancer Panel Type
9.3.2.2.3. By Cancer Type
9.3.2.2.4. By Application
9.3.2.2.5. By Technology
9.3.2.2.6. By End-User
9.3.3. South Africa Genomic Cancer Panel & Profiling Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tissue Testing
9.3.3.2.2. By Cancer Panel Type
9.3.3.2.3. By Cancer Type
9.3.3.2.4. By Application
9.3.3.2.5. By Technology
9.3.3.2.6. By End-User
10. SOUTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tissue Testing
10.2.2. By Cancer Panel Type
10.2.3. By Cancer Type
10.2.4. By Application
10.2.5. By Technology
10.2.6. By End-User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tissue Testing
10.3.1.2.2. By Cancer Panel Type
10.3.1.2.3. By Cancer Type
10.3.1.2.4. By Application
10.3.1.2.5. By Technology
10.3.1.2.6. By End-User
10.3.2. Colombia Genomic Cancer Panel & Profiling Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tissue Testing
10.3.2.2.2. By Cancer Panel Type
10.3.2.2.3. By Cancer Type
10.3.2.2.4. By Application
10.3.2.2.5. By Technology
10.3.2.2.6. By End-User
10.3.3. Argentina Genomic Cancer Panel & Profiling Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tissue Testing
10.3.3.2.2. By Cancer Panel Type
10.3.3.2.3. By Cancer Type
10.3.3.2.4. By Application
10.3.3.2.5. By Technology
10.3.3.2.6. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Agilent Technologies, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. ARUP Laboratories Inc
15.3. Burning Rock Biotech Limited
15.4. U.S. Caris MPI, Inc.
15.5. Danaher Corporation
15.6. Exact Sciences Corporation
15.7. F. Hoffmann-La Roche Ltd
15.8. Fulgent Genetics Inc.
15.9. Illumina, Inc.
15.10. Thermo Fisher Scientific Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
